Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    Pertuzumab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 11Perjeta

    02 7Phesgo

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Perjeta

    Pertuzumab

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Perjeta

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 3,628

    2018 Revenue in Millions : 2,856

    Growth (%) : 27

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Perjeta

    Pertuzumab

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Perjeta

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 4,326

    2019 Revenue in Millions : 3,924

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Phesgo

    Pertuzumab

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Phesgo

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 366

    2020 Revenue in Millions : 24

    Growth (%) : 1,378

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Perjeta

    Pertuzumab

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Perjeta

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 4,256

    2020 Revenue in Millions : 4,116

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Phesgo

    Pertuzumab, Trastuzumab, Hyaluronidase

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Phesgo

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab, Trastuzumab, Hyaluronidase

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 366

    2020 Revenue in Millions : 24

    Growth (%) : 1,378

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Phesgo

    Pertuzumab

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Phesgo

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 809

    2021 Revenue in Millions : 366

    Growth (%) : 121

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Phesgo

    Pertuzumab, Trastuzumab, Hyaluronidase

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Phesgo

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab, Trastuzumab, Hyaluronidase

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 809

    2021 Revenue in Millions : 366

    Growth (%) : 121

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Perjeta

    Pertuzumab

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Perjeta

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 4,468

    2021 Revenue in Millions : 4,256

    Growth (%) : 5

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Phesgo

    Pertuzumab, Trastuzumab, Hyaluronidase

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Phesgo

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab, Trastuzumab, Hyaluronidase

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,299

    2022 Revenue in Millions : 809

    Growth (%) : 51

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Phesgo

    Pertuzumab

    arrow
    BIOHK2025
    Not Confirmed

    Brand Name : Phesgo

    Switzerland
    arrow
    BIOHK2025
    Not Confirmed

    Roche

    Pertuzumab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,299

    2022 Revenue in Millions : 809

    Growth (%) : 51

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF